Lactobacillus paracasei (K71 / LP33) for Common Cold

Verdict: Insufficient Evidence

Across 3 PubMed studies, the evidence for Lactobacillus paracasei (K71 / LP33) in Common Cold grades Tier U — unverified / insufficient. Research is still too limited to draw a firm conclusion.

U ⚫ U Unverified Insufficient Evidence

🔬Why this grade7-layer evidence engine

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.41
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
U · Insufficient Evidence
Confidence
73%
Broadly consistent
Evidence level
E3
Single high-quality meta-analysis

How strongly each layer supports this effect

lower = less supportive
L11 AI re-checkIndependent read
0.20
L2 PubMedPrimary literature
0.40
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L5 Clinical bodiesAuthoritative stance
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.406
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — | C→U 因 scope.conflation_risk=true 且 L11 獨評較低 (B7-2 tier cap)
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (3)L2 · primary research & systematic reviews

Effect of long term consumption of a probiotic milk on infections in children attending day care centres (Hatakka et al.)
PMID: 11387176 2001 RCT (double-blind) n = 571
Finding: Children receiving LGG milk had fewer days of respiratory infection (mean reduction ~17%; RR 0.83, 95% CI 0.71-0.96) and reduced antibiotic use vs placebo.
⚠️ Industry-funded Effect size: RR 0.83 (95% CI 0.71-0.96) for respiratory infection days
View on PubMed
Randomised, double-blind, placebo-controlled study using new probiotic lactobacilli for strengthening the body immune defence against viral infections (Berggren et al.)
PMID: 20803023 2011 RCT (double-blind) n = 272
Finding: Probiotic group had reduced cold incidence (0.9 vs 1.0 episodes; p=0.069 trend) and significantly fewer symptom days (6.2 vs 8.6 days, p=0.0481); shorter pharyngeal symptom duration.
⚠️ Industry-funded Effect size: MD ~-2.4 days symptom duration (p=0.048)
View on PubMed
Probiotics for preventing acute upper respiratory tract infections
PMID: 36001877 2022 系統性回顧 n = 9,438
Finding: Probiotics probably reduce number of people with acute URTIs (OR 0.24, 95% CI 0.15-0.37; moderate-certainty evidence) and mean URTI duration (MD -1.22 days, 95% CI -2.12 to -0.33); strain-specific data sparse.
🟢 High quality Mixed funding Effect size: OR 0.24 (95% CI 0.15-0.37); MD -1.22 days duration
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L5a NIH Office of Dietary Supplements
Cautious
A review of 23 studies (1,919 participants) in which probiotics were tested for treating allergic rhinitis found some evidence that they may be helpful for improving symptoms and quality of life... because the studies tested different probiotics and measured different effects, no recommendations about the use of probiotics could be made. source↗
L5e Specialty Society (condition-mapped)
Not addressed
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬3 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-common-cold-INT-lactobacillus-paracasei-001 繁體中文版 →